Welcome to our dedicated page for Inozyme Pharma news (Ticker: INZY), a resource for investors and traders seeking the latest updates and insights on Inozyme Pharma stock.
Inozyme Pharma Inc. was a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases affecting bone health and blood vessel function. Its news centered on the PPi-Adenosine Pathway, the ENPP1 Fc fusion protein enzyme replacement therapy INZ-701, and clinical development for ENPP1 Deficiency, with additional references to related mineralization and vascular conditions.
Company updates also covered ENERGY trial data, disease natural-history publications, operating and financial results, program prioritization, healthcare-conference participation, governance and capital-structure matters, and the completed acquisition of Inozyme by BioMarin Pharmaceutical in July 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Inozyme Pharma (Nasdaq: INZY) announced that Yves Sabbagh, Ph.D., will present preliminary data from the ongoing Phase 1/2 clinical trial of INZ-701 in patients with ENPP1 Deficiency at the European Calcified Tissue Society Congress on April 17, 2023. The trial has shown positive preliminary pharmacokinetic, pharmacodynamic, and safety data, with ongoing dosing in the Phase 2 portion. The company plans to report interim data in Q3 2023 and add a new cohort for once-weekly dosing investigation.
ENPP1 Deficiency is a serious condition leading to high morbidity in infants and lacks approved therapies. The trial assesses INZ-701's safety and PK/PD profile, with exploratory endpoints focusing on calcification and functional outcomes.
Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on rare diseases, announced that Douglas A. Treco, Ph.D., CEO and Chairman, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, from 9:30 to 10:10 AM ET.
A live webcast of this event will be available on the Investor Relations section of Inozyme's website, along with a replay for a limited time.
Inozyme is developing INZ-701, an enzyme replacement therapy targeting pathologic mineralization and intimal proliferation associated with severe diseases. Currently, INZ-701 is in Phase 1/2 clinical trials for ENPP1 Deficiency and ABCC6 Deficiency.
Inozyme Pharma (Nasdaq: INZY) announced the grant of an inducement award to its newly appointed Chief Operations Officer, Matthew Winton, Ph.D., effective April 3, 2023. The award includes a nonstatutory option to purchase up to 250,000 shares at an exercise price of $5.39 per share, corresponding to the company's closing share price on the grant date. The option has a 10-year term and vests over four years. Inozyme Pharma specializes in developing therapeutics for rare diseases, including therapies like INZ-701 for pathologic mineralization, currently in Phase 1/2 clinical trials.
Inozyme Pharma (Nasdaq: INZY) announced the retirement of founding CEO Axel Bolte, effective April 1, 2023, with Douglas A. Treco, Ph.D. set to succeed him. Matthew Winton, Ph.D. has been appointed COO. Recent financial results for the year ending December 31, 2022, show a net loss of $67.1 million, or $1.78 per share. However, the company maintains a strong cash position of $127.9 million and expects to fund operations into Q4 2024. Ongoing clinical trials for INZ-701 show positive topline data, and the company is on track for pivotal trial initiation later this year.